3 Low-Priced Dividend Stocks Paying Over 5% Right Now
Alexandros Michailidis / iStock Editorial via Getty Images Pfizer The years after the pandemic haven't been kind to Pfizer Inc.
Terrible News for Pfizer Stock Investors
The past three years have been challenging for Pfizer (PFE 0.11%). Revenue and earnings have moved in the wrong direction, as has the company's share price.
2 High-Yield Dividend Stocks Yielding Over 6% That'll Pay You to Wait
High-yielding dividend stocks may not be the ticket to superior returns, but they can rank pretty high on the list of nice-to-haves for investors in retirement or those who could use a bit of extra...
Pfizer (PFE) CEO on Braftovi Reducing Colorectal Cancer Death Risk "in Half"
Dr. Albert Bourla, CEO of Pfizer (PFE), joins Nicole Petallides on Morning Trade Live to discuss the latest results of his company's Braftovi drug trials. According to Dr. Bourla, results showed it...
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression
An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to AstraZeneca's Faslodex in patients with a specific gene mutation, accordin...
Unlocking Pfizer's Value: Cost Controls And Oncology Pipeline
Despite recent underperformance, a "Buy" rating on Pfizer is reiterated due to a strong Q1 EPS beat, driven by significant cost controls and margin improvement, signaling operational strength. Mana...
Investing In The Promising PD1/VEGF Bispecific - Pfizer And Instil Could Be Good Candidates
Bispecific antibodies targeting PD1 and VEGF show promise in treating non-small cell lung cancer, with Summit Therapeutics' Ivonescimab outperforming Pembrolizumab in a Phase III trial. While immat...
1 Ultra-High-Yield Dividend Stock Down 57% to Buy Hand Over Fist
Most people like to buy products when prices are cheaper. That's why you'll probably see lots of car dealers, furniture stores, and retailers advertising special sales during the Memorial Day weekend.
Pfizer's 7.5% Dividend: Income Haven or House of Cards?
A dividend yield that surpasses 7.5% from a pharmaceutical sector giant like Pfizer Inc. NYSE: PFE certainly catches the eye of income-seeking investors.
Pfizer Looks Like A Great Play At Current Valuations
Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals versus peers. The company leads its peer group in EBITDA and revenue growt...
Pfizer Buys Rights to PD-1 & VEGF Inhibitor From China Biotech
PFE in-licenses global rights, ex-China, to SSGJ-707, from Chinese biotech, 3SBio for an upfront payment of $1.25 billion.
Pfizer Signs Experimental Drug Licensing Agreement With 3SBio
Pfizer inks Experimental Drug Licensing Deal With China-based company 3SBio.
These 3 Dividend Stocks Yield More Than 6% and Their Payouts Look Safe
If you see a stock that pays 6% in dividends, you might assume it's too risky -- but that's not always the case. In some situations, a yield can grow to such heights because investors have been dum...
Pfizer signs $6bn licensing deal with China's 3SBio for cancer drug
Pfizer Inc (NYSE:PFE, ETR:PFE) has agreed a licensing deal worth up to $6 billion with Chinese biopharmaceutical group 3SBio to develop and commercialise an experimental cancer treatment. The drug,...
Pfizer signs up to $6 billion licensing deal with China's 3SBio for cancer drug
Pfizer has signed a licensing agreement worth up to $6 billion with Chinese pharmaceutical products developer 3SBio Inc for the development, manufacturing and commercialization of a drug undergoing...
Related Companies